ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1664

TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Abstract Number: 1071

Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
Abstract Number: 1640

Tryptophan Metabolites Are Associated with Erosion and Symptoms in Hand Osteoarthritis: Results from the DIGICOD Cohort
Abstract Number: 0101

Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status
Abstract Number: 0039

Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases
Abstract Number: 0689

Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
Abstract Number: 1254

Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
Abstract Number: 2230

Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
Abstract Number: 1790

Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?
Abstract Number: 1233

Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
Abstract Number: 2229

Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Abstract Number: 0468

Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
Abstract Number: 0798

Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Abstract Number: 1919

Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
Abstract Number: 0669

Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].